Management of metastatic castration-resistant prostate cancer after first-line docetaxel

European Journal of Cancer

Volumn 47, Issue 14, 2011, Pages 2133-2142

  Harrington, J A ^a   Jones, R J ^b  

^a Li Ka Shing Centre   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Anti angiogenic agents; Castration resistant prostate cancer; Clusterin targeted therapy; Cytotoxic therapy; Docetaxel; Hormonal therapy; Immunotherapy; Second line

Indexed keywords

4 [3 [4 CYANO 3 (TRIFLUOROMETHYL)PHENYL] 5,5 DIMETHYL 4 OXO 2 THIOXO 1 IMIDAZOLIDINYL] 2 FLUORO N METHYLBENZAMIDE; ABIRATERONE ACETATE; BEVACIZUMAB; CABAZITAXEL; CALCITRIOL; CUSTIRSEN; DEXAMETHASONE; DIETHYLSTILBESTROL; DIETHYLSTILBESTROL PHOSPHATE; DOCETAXEL; EPOTHILONE B; ERIBULIN; GLUCOCORTICOID; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; IPILIMUMAB; IXABEPILONE; KETOCONAZOLE; MITOXANTRONE; PLACEBO; PREDNISOLONE; PREDNISONE; PROVENGE; SATRAPLATIN; SUNITINIB; THALIDOMIDE; XL 184;

ANOREXIA; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; CHILL; DIARRHEA; DRUG DOSE ESCALATION; DRUG MEGADOSE; FATIGUE; FEBRILE NEUTROPENIA; FEVER; FLU LIKE SYNDROME; FLUID RETENTION; HEADACHE; HEART DISEASE; HEPATITIS; HUMAN; HYPERTENSION; HYPOKALEMIA; LEG EDEMA; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUTROPENIA; PRIORITY JOURNAL; RASH; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; THROMBOEMBOLISM;

EID: 80052527251     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2011.04.036     Document Type: Article

References (73)

1. R.J. Bryant, and F.C. Hamdy Screening for prostate cancer: an update Eur Urol 53 2008 37 44 (Pubitemid 350166725)
2. J. Ferlay, D.M. Parkin, and E. Steliarova-Foucher Estimates of cancer incidence and mortality in Europe in 2008 Eur J Cancer 4 2010 765 781
3. Bray F. The burden of cancer in Europe. In: Coleman MP, Alexe D-M, Albrecht T, McKee M, editors. Responding to the challenge of cancer in Europe. Institute of Public Health of the Republic of Slovenia; 2008: pp. 7-39.
4. K.N. Chi, A. Bjartell, and D. Dearnaley Castration-resistant prostate cancer: from new pathophysiology to new treatment targets Eur Urol 56 2009 594 605
5. I.F. Tannock, R. de Wit, and W.R. Berry Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 2004 1502 1512 (Pubitemid 39315317)
6. National Institute for Health and Clinical Excellence. Docetaxel for the treatment of hormone refractory metastatic prostate cancer. Technology appraisal guidance 101; June 2006. Available at: http://www.nice.org.uk/TA101 (accessed October 2010).
7. L. Moser, T. Schubert, and W. Hinkelbein Hormone-refractory and metastatic prostate cancer-palliative radiotherapy Front Radiat Ther Oncol 41 2008 117 125
8. D.P. Petrylak, C.M. Tangen, and M.H. Hussain Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer N Engl J Med 351 2004 1513 1520 (Pubitemid 39315318)
9. I.F. Tannock, D. Osoba, and M.R. Stockler Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points J Clin Oncol 14 1996 1756 1764 (Pubitemid 26185452)
10. P.W. Kantoff, S. Halabi, and M. Conaway Hydrocortisone with or without mitoxantrone in men with hormone refractory prostate cancer: results of the cancer and leukaemia group B 9182 study J Clin Oncol 17 1999 2506 2513 (Pubitemid 29368252)
11. D.R. Berthold, G. Pond, and M. Rossner Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, quality of life response and survival in the TAX 327 study Clin Cancer Res 14 2008 2763 2767
12. A. Kelly, S. Halabi, and M.A. Carducci A randomized, double-blind, placebo controlled phase III trial comparing docetaxel, prednisone, placebo with docetaxel, prednisone, bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): survival results of CALGB 90401 J Clin Oncol 28 2010 18s (abstract LBA4511)
13. J.E. Rosenberg, V.K. Weinberg, and W.K. Kelly Activity of second-line chemotherapy in docetaxel refractory hormone refractory prostate cancer patients: randomized phase 2 study of ixabepilone or mitoxantrone and prednisone Cancer 110 2007 556 563 (Pubitemid 47106144)
14. M.-C. Bissery Preclinical evaluation of new taxoids Curr Pharm Des 7 2001 1251 1257 (Pubitemid 32798807)
15. P.G. Morris, and M.N. Fornier Microtubule active agents: beyond the taxane frontier Clin Cancer Res 14 2008 7167 7172
16. X. Pivot, P. Koralewski, and J.L. Hidalgo A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients Ann Oncol 19 2008 1547 1552
17. A.C. Mita, L.J. Denis, and E.K. Rowinsky Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors Clin Cancer Res 15 2009 723 730
18. J.S. de Bono, S. Oudard, and M. Ozguroglu Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial Lancet 376 2010 1147 1154
19. T. Latif, L. Wood, and C. Connell Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily x5 in hormone refractory prostate cancer (HRPC) Invest New Drugs 23 2005 79 84 (Pubitemid 39505954)
20. C.N. Sternberg, P. Whelan, and J. Hetherington Phase III trial of satraplatin, an oral platinum plus prednisone vs. Prednisone alone in patients with hormone-refractory prostate cancer Oncology 68 2005 2 9 (Pubitemid 40675002)
21. C.N. Sternberg, D.P. Petrylak, and O. Sartor Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial J Clin Oncol 27 2009 5431 5438
22. J. Michels, T. Montemurro, and N. Murray First and second line chemotherapy with docetaxel or mitoxantrone in patients with hormone refractory prostate cancer: does sequence matter? Cancer 106 2006 1041 1046
23. D.R. Berthold, G.R. Pond, and R. de Wit Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa Ann Oncol 19 2008 1749 1753
24. J. Ansari, S.A. Hussain, and A. Zarkar Docetaxel chemotherapy for metastatic hormone refractory prostate cancer as first-line palliative chemotherapy and subsequent re-treatment: Birmingham experience Oncol Rep 20 2008 891 896
25. T.M. Beer, C.W. Ryan, and P.M. Venner Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer: results from ASCENT, a double blinded, randomised comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel Cancer 112 2008 326 330
26. Fuxius S, Mueller A, Kleitz K, et al. Weekly docetaxel re-challenge in patients with hormone-resistant prostate cancer refractory to conventionally three weekly docetaxel. J Clin Oncol 2010;28. Available at: http://jco.ascopubs. org/gca?allch=citmgr&submit=Go&gca=ascomtg%3B28%2F15 -suppl%2Fe15004 (accessed Oct 2010).
27. S. Goodin, M.P. Kane, and E.H. Rubin Epothilones: mechanism of action and biologic activity J Clin Oncol 22 2004 2015 2025 (Pubitemid 41095195)
28. M. Hussain, C.M. Tangen, and P.N. Lara Jr Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naïve patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial J Clin Oncol 23 2005 8724 8729 (Pubitemid 46211517)
29. J.E. Rosenberg, C.J. Ryan, and V.K. Weinberg Phase I study of ixabepilone, mitoxantrone and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the Department of Defense Prostate Cancer Clinical Trials Consortium J Clin Oncol 27 2009 2772 2778
30. E. Beardsley, F. Saad, F. Venner, and Y. Winquist A phase II study of patupilone in patients (pts) with metastatic castrate-resistant prostate cancer (CRPC) who have progressed after docetaxel J Clin Oncol 27 2009 15s (abstract 5139)
31. De Bono JS, Maroto P, Calvo E, et al. Phase II study of eribulin mesylate (E7389) in patients (pts) with metastatic castration-resistant prostate cancer (CRPC) stratified by prior taxane therapy. ASCO Genitourinary Cancers Symposium 2009; (abstract 166).
32. C.A. Heinlein, and C. Chang Androgen receptor in prostate cancer Endocr Rev 25 2004 276 308 (Pubitemid 38501396)
33. H.I. Scher, T.M. Beer, and C.S. Higano Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study Lancet 375 2010 1437 1446
34. Oh W, Hurwitz M, D'Amico A, Richie J, Kantoff P. Neoplasms of the prostate. In: Kufe DW, Pollock RE, Weischelbaum RR, et al., editors. Holland-Frei Cancer Medicine, 6th edition, Hamilton: BC Decker; 2003.
35. K. Akakura, H. Suzuki, and T. Ueda Possible mechanism of dexamethasone therapy for prostate cancer: suppression of circulating level of interleukin-6 Prostate 56 2003 106 109 (Pubitemid 41490326)
36. A. Yano, Y. Fujii, and A. Iwai Glucocorticoids suppress tumour angiogenesis and in vivo growth of prostate cancer cells Clin Cancer Res 12 2006 3003 3009 (Pubitemid 43837344)
37. I. Tannock, M. Gospodarowicz, and W. Meakin Treatment of metastatic prostate cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response J Clin Oncol 7 1989 590 597 (Pubitemid 19126794)
38. M. Morioka, T. Kobayashi, and Y. Furukawa Prostate-specific antigen levels and prognosis in patients with hormone-refractory prostate cancer treated with low-dose dexamethasone Urol Int 68 2002 10 15 (Pubitemid 34102566)
39. K. Nishimura, N. Nonomura, and Y. Yasunaga Low doses of oral dexamethasone for hormone-refractory prostate carcinoma Cancer 89 2000 2570 2576 (Pubitemid 32011601)
40. R. Venkitaraman, K. Thomas, and R.A. Huddart Efficacy of low-dose dexamethasone in castration-refractory prostate cancer BJU Int 101 2008 440 443 (Pubitemid 351160930)
41. L.G. Horvath, S.M. Henshall, and C.S. Lee Frequent loss of estrogen receptor-β expression in prostate cancer Cancer Res 61 2001 5331 5335 (Pubitemid 32694904)
42. W.K. Oh The evolving role of oestrogen therapy in prostate cancer Clin Prostate Cancer 1 2002 81 89 (Pubitemid 37012404)
43. C. Serrate, Y. Loriot, and T. De La Motte Rouge Diethylstilbestrol (DES) retains activity, is a reasonable option in patients previously treated with docetaxel for castration-resistant prostate cancer Ann Oncol 20 2009 965
44. D.E. Johnson, R.J. Babaian, and A.C. von Eschenbach Ketoconazole therapy for hormonally refractive metastatic prostate cancer Urology 31 1988 132 134 (Pubitemid 18066271)
45. D.L. Trump, K.H. Havlin, and E.M. Messing High-dose ketoconazole in advanced hormone-refractory prostate cancer: endocrinologic and clinical effects J Clin Oncol 7 1989 1093 1098 (Pubitemid 19196533)
46. E.J. Small, A.D. Baron, L. Fippin, and D. Apodaca Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal J Urol 157 1997 1204 1207 (Pubitemid 27130781)
47. E.J. Small, S. Halabi, and N.A. Dawson Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial CALGB9583 J Clin Oncol 22 2004 1025 1033 (Pubitemid 41095034)
48. W.D. Figg, S. Woo, and W. Zhu A phase I clinical study of high dose ketoconazole plus weekly docetaxel for metastatic castration resistant prostate cancer J Urol 183 2010 2219 2226
49. M. Nakabayashi, W.K. Oh, and S. Jacobus Activity of ketoconazole after taxane-based chemotherapy in castration-resistant prostate cancer BJU Int 105 2009 1392 1396
50. M.D. Galsky, K. Simon, and G. Sonpavde Ketoconazole retains activity in patients with docetaxel-refractory prostate cancer Ann Oncol 20 2009 965 966
51. A.H.M. Reid, G. Attard, and D.C. Danila Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate J Clin Oncol 28 2010 1489 1495
52. G. Attard, A.H. Reid, and T.A. Yap Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven J Clin Oncol 26 2008 4563 4571
53. D.C. Danila, M.J. Morris, and J.S. de Bono Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer J Clin Oncol 28 2010 1496 1501
54. G. Attard, A.H. Reid, and R. A'Hern Selective inhibition of CYP 17 with abiraterone acetate is highly active in the treatment of castrate-resistant prostate cancer J Clin Oncol 27 2009 3742 3748
55. D.C. Danila, M.J. Morris, and J.S. de Bono Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer J Clin Oncol 28 2010 1496 1501
56. J.S. De Bono, C.J. Logothetis, and K. Fizazi Abiraterone acetate (AA) plus low dose prednisone (P) improves overall survival (OS) in patients (PTS) with metastatic castration-resistant prostate cancer (mCRPC) who have progressed after docetaxel-based chemotherapy (chemo): results of COU-AA-301, a randomized double-blind placebo-controlled phase III study Ann Oncol 21 2010 viii3 (abstract LBA5)
57. Mulcahy N. Phase 3 trial of immunotherapy for metastatic prostate cancer terminated. Available at: http://www.medscape.com/viewarticle/582220 (accessed October 2010).
58. Ferris S. Cell Genesys halts VITAL-2 GVAX trial in advanced prostate cancer. Available at: http://www.drugs.com/news/cell-genesys-halts-vital2-gvax trial-advanced-prostate-cancer-13371.html (accessed October 2010).
59. E.J. Small, P.F. Schellhammer, and C.S. Higano Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer J Clin Oncol 24 2006 3089 3094 (Pubitemid 46638945)
60. P.W. Kantoff, C.S. Higano, and N.D. Shore Sipuleucel-T immunotherapy for castration-resistant prostate cancer N Engl J Med 363 2010 411 422
61. Kantoff P, Higano CS, Berger ER, et al. Updated survival results of the IMPACT trial of sipuleucel-T for metastatic castration-resistant prostate cancer. ASCO Genitourinary Cancers Symposium 2011; (abstract 8).
62. S. O'Day, F.S. Hodi, and D.F. McDermott A phase III, randomized, double-blind, multicenter study comparing monotherapy with ipilimumab or gp100 peptide vaccine, the combination in patients with previously treated, unresectable stage III or IV melanoma J Clin Oncol 28 2010 18s (abstract 4)
63. S.F. Slovin, T.M. Beer, and C.S. Higano Initial phase II experience of ipilimumab (IPI) alone, in combination with radiotherapy (XRT) in patients with metastatic castration-resistant prostate cancer (CRPC) J Clin Oncol 27 2009 15s (abstract 5138)
64. Y.M. Ning, J.L. Gulley, and P.M. Arlen Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer J Clin Oncol 28 2010 2070 2076
65. G. Sonpavde, P.O. Periman, and D. Bernold Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy Ann Oncol 21 2010 319 324
66. W.L. Dahut, C. Scripture, and E. Posadas A phase II clinical trial of sorafenib in androgen-independent prostate cancer Clin Cancer Res 14 2008 209 214 (Pubitemid 351377997)
67. D.C. Smith, M.R. Smith, and E.J. Small Phase II study of XL184 in a cohort of patients (pts) with castration-resistant prostate cancer (CRPC), measurable soft tissue disease J Clin Oncol 29 2011 7s (abstract 127)
68. K.N. Chi, A. Zoubeidi, and M.E. Gleave Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin for the treatment of cancer Expert Opin Investig Drugs 17 2008 1955 1962
69. K.N. Chi, S.J. Hotte, and E.Y. Yu Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer J Clin Oncol 28 2010 4247 4254
70. Saad F, Hotte SJ, North SA, et al. A phase II randomized study of custirsen (OGX-011) combination therapy in patients with poor-risk hormone refractory prostate cancer (HRPC) who relapsed on or within 6 months of 1st-line docetaxel therapy. J Clin Oncol 2008;26. Available at: http://jco.ascopubs.org/ gca?allch=&submit=Go&gca=ascomtg%3B26%2F15-suppl%2F5002 (accessed Oct 2010).
71. J.S. De Bono, H.I. Scher, and R.B. Montgomery Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer Clin Cancer Res 14 2008 6302 6309
72. H.I. Scher, S. Halabi, and I. Tannock Design and endpoints of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the prostate cancer clinical trials working group J Clin Oncol 26 2008 1148 1159
73. A.J. Armstrong, E. Garrett-Mayer, and R. de Wit Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer Clin Cancer Res 16 2010 203 211